4crb: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:


Description: Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
Description: Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
[[Category: Unreleased Structures]]
[[Category: Tigerstrom, A]]
[[Category: Roth, R]]
[[Category: Gustafsson, D]]
[[Category: Nilsson, I]]
[[Category: Kang, D]]
[[Category: Karis, D]]
[[Category: Oster, L]]
[[Category: Akkaya, S]]
[[Category: Olsson, T]]
[[Category: Knecht, W]]
[[Category: Beisel, H.G]]
[[Category: Nerme, V]]
[[Category: Jurva, U]]
[[Category: Erixon, K]]
[[Category: Fjellstrom, O]]
[[Category: Eriksson, P.O]]
[[Category: Redzic, A]]
[[Category: Sandmark, J]]

Revision as of 16:28, 24 December 2014

Unreleased structure

The entry 4crb is ON HOLD until Paper Publication

Authors: Sandmark, J., Oster, L., Fjellstrom, O., Akkaya, S., Beisel, H.G., Eriksson, P.O., Erixon, K., Gustafsson, D., Jurva, U., Kang, D., Karis, D., Knecht, W., Nerme, V., Nilsson, I., Olsson, T., Redzic, A., Roth, R., Tigerstrom, A.

Description: Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA